Ocugen Stock News

Los Angeles, California--(Newsfile Corp. - June 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocug

After the FDA rejected Covaxin, Ocugen has almost no chance of generating profits from the shot. OCGN stock is a great short.

MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseas

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by 2.12% yesterday. This is why it happened.

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN).  Such investors are advised to cont

NEW YORK, June 15, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ocugen, Inc. (NAS

OCGN stock saw a glimmer of hope today. Where the company took a hit last week in deserting EUA, it is gaining today with a new partnership.

The biotech is bolstering its production capabilities for an experimental coronavirus vaccine.

The shares of biopharmaceutical concern Ocugen Inc (NASDAQ:OCGN) are surging this afternoon, last seen up 7.2% to trade at $6.56.

Ocugen Inc (NASDAQ: OCGN) has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVID-19 vaccine candidate, Covaxin for the U.S. and Canadian markets. "Securi

Shares of Ocugen Inc. gained 14.3% in premarket trading on Tuesday after the company said it picked Jubilant HollisterStier, a privately held pharmaceutical contract manufacturer, to produce its still

XBI: Alzheimer's Drug Approval Supports Renewed Bullish Industry Sentiment

Jubilant HollisterStier to manufacture COVAXIN™ in the US Jubilant HollisterStier to manufacture COVAXIN™ in the US

Here are three steps to take.

Searching for stocks to buy that could legitimately double before 2022? These seven are in position to do just that.